SMMT | Summit Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	22.84 - 24.35
52 Week Range	2.1000 - 36.91
Beta	0.49
Implied Volatility	115.05%
IV Rank	26.81%
Day's Volume	4,347,792
Average Volume	3,783,662
Shares Outstanding	737,679,700
Market Cap	17,792,834,364
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-03-05

Valuation
Profitability
Growth
Health
P/E Ratio	-77.81
Forward P/E Ratio	N/A
EPS	-0.31
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	105
Country	USA
Website	SMMT

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

SMMT's peers: EPIX, NKTX, CGEM, KZR, KRON, ZVSA, OCEA, ZURA, ELEV, ICVX, PHIO, SONN, ATNF, CDIO

*Chart delayed

Analyzing fundamentals for SMMT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SMMT Fundamentals page.

Watching at SMMT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SMMT Technicals page.